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Abstract The use of atorvastatin is rapidly increasing
among statins since the introduction of generics. However,
only limited data are available on its current use and the
effectiveness outside of randomised trials. The aim of the
study was to assess low-density lipoprotein (LDL-C) levels
in ambulatory patients at very high cardiovascular risk on
atorvastatin therapy in physician’s offices. A total of 2625
high-risk patients on atorvastatin were included into this
cross-sectional study by 539 office-based physicians
between June and December 2014. 47.0 % of the patients
had documented coronary heart disease (CHD), 25.1 %
type 2 diabetes mellitus (DM), and 27.9 % CHD plus
concomitant DM. The mean age was 66.1 ± 10.8 years,
62.1 % were male. Atorvastatin at the dose of 10, 20, 40
and 80 mg/day was administered in 15.6, 45.7, 33.9, and
4.8 % of the patients, respectively. The treatment duration
was 92.6 ± 109.6 weeks. The mean atorvastatin dose at
therapy start was 24.8 ± 15.2 mg/day and at time of doc-
umentation 27.9 ± 15.8 mg/day. Low-density lipoprotein
cholesterol (LDL-C)\70 mg/dL was achieved by 10.5 %
of the total cohort (7.5 % in DM, 9.3 % in CHD, and
15.2 % in CHD ? DM). In contrast, according to physi-
cians’ subjective assessment, 62.7 % of patients (with
small differences between groups) had reached their indi-
vidual LDL-C target. In summary, higher doses of ator-
vastatin are not frequently used in clinical practice. The
LDL-C target level\70 mg/dL as recommended by cur-
rent guidelines is achieved only in a minority of atorvas-
tatin treated patients at very high cardiovascular risk.
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Background
Low-density lipoprotein cholesterol (LDL-C) serum con-
centrations correlate with cardiovascular (CV) risk and
lowering of LDL-C reduces CV events. Based on many
large randomized clinical studies, LDL-C lowering with
statins is recommended for the secondary prevention of
cardiovascular outcomes [5, 33, 36]. The current European
guidelines (issued 2011 by EAS/ESC) [33] as well as the
US guidelines [36] (issued 2013 by AHA/ACC) on the
treatment of hyperlipidaemia pose particular emphasis on
patients with very high cardiovascular risk and recommend
stringent LDL-C lowering with statins. While the US
guidelines recommend fixed high doses (e.g,. atorvastatin
80 mg) for high-risk individuals [36], the European
guidelines recommend a treatment goal of LDL-
C\70 mg/dL or a[50 % LDL-C reduction [33].
According to a recent German study in primary care, the
prevalence of diagnosed coronary heart disease (CHD) is
12 %, and of diabetes mellitus type 2 (DM) 15 % [31].
Both diseases often present concomitantly [31]. Patients
with either CHD or DM (and those with stroke, peripheral
arterial disease or chronic renal insufficiency) are at very
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high risk and can especially benefit from lipid lowering
[33].
The utilization of statins in Germany increased steadily
in the recent years, up to 1707 million daily doses in 2013
for all statins combined [17]. Because of its designation as
lead substance within this group in 2006, simvastatin was
most widely prescribed in the past. However, since intro-
duction of atorvastatin as generic drug in March 2013, for
this agent 250 million daily doses were administered, with
further increase anticipated [17]. Among the generic sta-
tins, atorvastatin is perceived as the most potent agent and
atorvastatin will likely be the most frequently prescribed
statin in the near future [13, 20, 27].
Despite the increasing use of atorvastatin, current
information on the drug under clinical practice conditions
is limited compared to evidence on simvastatin in this
setting [11, 37] Against this background, the cross-sec-
tional study DISCOVER was initiated to assess the stan-
dard of care in ambulatory patients at very high
cardiovascular risk, treated with atorvastatin monotherapy
(original drug or generics).
Methods
DISCOVER was performed as retrospective, cross-sec-
tional study in the offices of 539 physicians in all
regions of Germany between June and December 2014.
Study materials were approved by the ethics committee
of the Bavarian Physicians Chamber in Munich on 8
May 2014. DISCOVER was registered in the vfa study
database (No. 931). Cardiologists, diabetologists, inter-
nists and general practitioners agreed to enter data of up
to first five eligible patients into the electronic case
collection form.
Patients were eligible for documentation if they met the
following criteria:
– C18 years of age at the documentation visit;
– diagnosed CHD, diagnosed DM, or both conditions
concomitantly (CHD ? DM);
– current treatment with atorvastatin, stable for at least
1 month;
– LDL-C laboratory value available.
Patients on other lipid-lowering therapies were not eli-
gible. The following data were collected: age, gender,
weight, height, and waist circumference, health insurance
status (statutory or private), index diagnoses (DM, CHD),
smoking, arterial hypertension, cardiovascular events in the
patient history (myocardial infarction, stroke, and transient
ischaemic attack), previous cardiac interventions [e.g.,
percutaneous coronary intervention (PCI), coronary artery
bypass grafting (CABG)].
Atorvastatin therapy was documented with the current
daily dose (mg/day), the treatment duration and the daily
dose at the start of the treatment. Concomitant medication
for the treatment of CHD and DM was also recorded.
Further information on other statins or other lipid-lowering
drugs used in the past was documented.
Systolic and diastolic blood pressure values were
recorded, as were laboratory values to assess blood fasting
glucose and HbA1c in diabetic patients, and lipid values
(total cholesterol, LDL-C, HDL-C, triglycerides) in all
patients. Physicians assessed the lipid-lowering target
achievement on atorvastatin treatment (yes/no), and the
satisfaction with current lipid-lowering treatment with
atorvastatin (yes/no).
A quality management system was implemented and
standard operating procedures (SOPs) were used to ensure
that the study was conducted and data were generated,
documented, and reported in compliance with the protocol.
Upon submission of data, each investigator verified all
recorded data to be accurate. Additionally, queries were
generated by data management during and after the study
to resolve any questions and implausible data. Implausible
data that could not be clarified were deleted from the
database. For the analysis, missing values were not
replaced. The entries ‘‘unknown’’ and ‘‘not collected’’ were
treated like missing values.
Statistical methods
Categorical variables were shown as absolute and adjusted
relative frequencies including the number of missing val-
ues in each category. Continuous variables were to be
presented as means with standard deviation, median,
quartiles, minimum value and maximum value, and num-
ber of known values. The statistical analysis system (SAS)
software package, release 9.2 (Cary, NC, U.S.A.) was used.
Results
Physicians
A total of 539 physicians contributed to the study. The
majority (n = 418; 78 %) documented five patients. Of the
2625 patients included, 1699 visited the office of a general
practitioner, 687 an internist, 175 patients a cardiologist,
and 221 a diabetologist (some physicians had more than
one specialization).
Characteristics
Characteristics are shown in Table 1. 1233 patients had
CHD (47.0 %), 658 patients DM (25.1 %), and 734 CHD
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plus DM (27.9 %). The mean age of the patients was
66.1 ± 10.8 years (range 19.0–93.0 years). Males were
more frequently included than females (62.1 versus
37.9 %). The majority of patients were in the statutory
health insurance (89.6 %), while a smaller share had pri-
vate insurance (10.4 %).
Treatment
Atorvastatin was administered in a wide dosing range up to
80 mg/day. The mean dose at therapy initiation was
24.8 ± 15.2 mg/day, and at the time of documentation
27.9 ± 15.8 mg/day, with no major differences between
the groups (CHD 28.6 ± 16.3 mg/day, DM
24.6 ± 13.3 mg/day, CHD ? DM 29.8 ± 16.4 mg/day).
The 10, 20, 40 and 80 mg/day atorvastatin doses were
administered in 15.6, 45.7, 33.9, and 4.8 % of the patients,
respectively, without relevant differences across sub-
groups. Mean treatment duration was 92.6 ± 109.6 weeks
(range 4–886 weeks) before the documentation date, with
no major differences between treatment groups. There was
no association between the atorvastatin dose (neither at
initiation of therapy or at documentation) and the treatment
duration.
Laboratory values and blood pressure
The mean value for LDL-C was 116.3 ± 42.6 mg/dl, for
total cholesterol 194.5 ± 50.6 mg/dl, for HDL-C 52.2 ±
17.7 mg/dl, and for triglycerides 172.4 ± 101.0 mg/dl. As
shown in Table 2, TC and LDL-C were somewhat lower in
the CHD ? DM group, HDL-C was higher and triglyc-
erides were lower in the CHD group. Patients in the DM
group exhibited higher TC, LDL-C, and triglyceride values
compared to the other groups.
Mean systolic blood pressure was 133.3 ± 13.3 mmHg,
and diastolic blood pressure 79.6 ± 8.4 mmHg. The mean
systolic value was lower in the CHD group compared to the
other subgroups, while the mean diastolic values were
similar across groups.
LDL-C target level achievement
The distribution of LDL-C values in the total cohort is
shown in Fig. 1. The LDL-C target value of\70 mg/dL
was achieved only by 10.5 % of the patients overall. The
rate was lowest in the DM group (7.5 %) and somewhat
higher in the CHD group (9.3 %) and the DM ? CHD













Age (years) n = 2622 n = 1232 n = 658 n = 732 \0.001a
Mean ± SD 66.1 ± 10.8 65.8 ± 11.0 63.8 ± 10.9 68.7 ± 9.9
Range 19.0–93.0 19.0–93.0 33.0–92.0 36.0–93.0
Sex, n (%) n = 2625 n = 1233 n = 658 n = 734 \0.001b
Male 1630 (62.1) 818 (66.3) 329 (50.0) 483 (65.8)
Female 995 (37.9) 415 (33.7) 329 (50.0) 251 (34.2)
Body mass index (kg/m2) 2422 1108 617 697 \0.001a
Mean ± SD 28.9 ± 4.7 27.5 ± 3.9 30.1 ± 5.4 29.9 ± 4.7
Arterial hypertension, n (%) 2198 (86.6) 987 (83.7) 526 (82.6) 685 (94.7) \0.001a
Family history of CHD, n (%) 1073 (60.7 %) 542 (63.6) 202 (45.7) 329 (69.6)
Previous MI, n (%) 853 (34.1) 487 (41.9) 21 (3.4) 345 (48.3)
Previous PCI, n (%) 900 (36.3) 547 (47.5) 13 (2.1) 340 (48.3)
Previous CABG, n (%) 351 (14.0) 203 (17.4) 10 (1.6) 138 (19.4)
Microalbuminuria, n (%) 311 (14.2) 23 (2.4) 108 (18.5) 180 (27.5) \0.001a
Previous stroke, n (%) 159 (6.4) 68 (5.9) 35 (5.6) 56 (7.9) \0.001a
Previous TIA, n (%) 180 (7.2) 83 (7.2) 26 (4.2) 71 (10.0) \0.001a
Values are n (%) if not stated otherwise
CABG coronary artery bypass graft, CHD coronary heart disease, DM diabetes mellitus, SD standard
deviation
P values were calculated by a Kruskal–Wallis test or b Chi-square test
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Table 2 Lipid values, blood pressure and blood glucose









Total cholesterol, mg/dL n = 2499 n = 1157 n = 631 n = 711 \0.001
194.6 ± 50.6 194.1 ± 50.1 203.4 ± 50.7 187.5 ± 50.1
LDL-C, mg/dL n = 2612 n = 1227 n = 653 n = 732 \0.001
116.3 ± 42.6 115.8 ± 41.0 123.9 ± 44.4 110.2 ± 42.6
HDL-C, mg/dL n = 2416 n = 1120 n = 607 n = 689 \0.001
52.2 ± 17.7 54.8 ± 19.2 51.8 ± 16.6 48.4 ± 15.0
Triglycerides, mg/dL n = 2392 n = 1104 n = 602 n = 686 \0.001
172.4 ± 101.0 150.6 ± 78.3 193.1 ± 117.3 189.5 ± 110.5
Systolic blood pressure, mmHg n = 2503 n = 1161 n = 629 n = 713 \0.001
133.3 ± 13.3 131.5 ± 13.3 135.1 ± 12.9 134.7 ± 13.4
Diastolic blood pressure, mmHg n = 2497 n = 1160 n = 627 n = 710 \0.001
79.6 ± 8.4 79.0 ± 8.2 80.7 ± 8.6 79.5 ± 8.6
HbA1c, % n = 1658 n = 346 n = 620 n = 692 \0.001
6.6 ± 1.4 5.2 ± 1.8 7.0 ± 1.0 7.0 ± 1.0
Fasting glucose, mg/dL n = 2040 n = 799 n = 574 n = 667 \0.001
115.4 ± 37.9 91.6 ± 19.7 127.5 ± 38.1 133.5 ± 39.3
All values are mean ± standard deviation, if not indicated otherwise
P values were calculated by Kruskal–Wallis test
CHD coronary heart disease, DM diabetes mellitus
Fig. 1 Histogram of LDL-C
categories at the documentation
visit. P\ 0.001 (Chi-square
test) each for the comparison of
the CHD, DM and CHD ? DM
groups with respect to LDL-
C\70 mg/dL, or with respect
to treating physician’s
assessment
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Target level achievement rates were not associated with the
duration of atorvastatin treatment. Patients who met the LDL-
C target compared to those who did not had similar treatment
duration (93.1 ± 96.3 versus 92.7 ± 111.3 weeks).
The distribution of atorvastatin dosage categories
(mg/day) was similar across all LDL-C categories (Fig. 3).
The subjective physician assessment of target achieve-
ment substantially deviated from the laboratory values.
While 10.5 % of patients who had not achieved the target
according to the LDL-C criterion (\70 mg/dL), 62.7 %
were assessed by their physicians to have clinically met the



































Fig. 2 LDL-C target attainment
by laboratory results (\70 mg/
dL) and subjective physician
assessment. Figure shows the
percentages of patients with
LDL-C\70 mg/dl (blue bars)
and in comparison the
percentages of patients that
were judged by their physicians
to have clinically met their
individual LDL-C target
Fig. 3 Distribution of atorvastatin dosages by LDL-C category. The distribution of atorvastatin dosage categories (mg/day) was similar across
all LDL-C categories
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Overall, 74.3 % of physicians were satisfied with the
atorvastatin therapy, with marginal differences across
subgroups. However, satisfaction decreased with increas-
ing atorvastatin dose: 78.8 % of physicians were satisfied
with the 10 mg/day dose in contrast to 63.2 % with the
80 mg/day dose.
Discussion
The two main findings of this contemporary cross-sectional
analysis are that patients at very high cardiovascular risk
treated with atorvastatin receive relatively low doses and
that only a minority of the patients achieved an LDC-C
below\70 mg/dL.
Lipid abnormalities are highly prevalent under clinical
practice conditions [6, 9, 10, 12, 37]. Despite the docu-
mented benefit of statin therapy and the consensus of the
guidelines on intensive treatment for high-risk patients, the
standard of care documented in this large contemporary
sample reveals a substantially different situation. The
incomplete implementation of guideline recommendations
supports data from US office-based cardiologists who did
not use statins in 32.4 % of those patients who were eli-
gible for such medication [21]. In other countries similar
findings were reported [34, 35]. In the EUROASPIRE IV
study in 76 centers of 24 European countries an improved
situation in the management of CHD patients was shown:
at least on the short term statins were administered to
85.7 % of eligible patients (with or without other cardio-
protective medications) [18]. This represents a clear
improvement to an earlier study in Germany, in which the
treatment rates with statins (and other cardioprotective
medications) decreased substantially over time: after
5 years only 17 % of eligible patients, who originally had
received statins, were still on such agents [22]. Our study
now provides evidence that even in the patients that receive
a potent statin, a majority of patients receives a low dose.
Atorvastatin, introduced in 1996, is a well-studied statin
with high potency to lower elevated LDL-C levels. It is
prescribed to a large portion of statin-treated patients
around the world. Data from randomized trials suggest that
the full dose of 80 mg atorvastatin can lower LDL-C by
45–55 % [19, 25, 29]. Indeed, for atorvastatin the ‘‘fire and
forget strategy’’ was propagated based on the assumption
owing to its strong LDL-C lowering effect the drug would
not require follow-up examination [4]. However, this
assumption only applies for the drug given at high doses
[33]. In an analysis of the VOYAGER database, 40 or
59 % of patients on atorvastatin 40 or 80 mg/day achieved
more than 50 % decrease of LDL-C [15]. This strong
lowering of LDL-C by atorvastatin was associated with a
reduction of major coronary events across all investigated
risk groups [26].
To our knowledge, current observational data on ator-
vastatin use and effectiveness in clinical practice is limited
to two reports. In the UK, of 2999 high-risk patients
(60.2 % men; mean age 67.9 ± 10.6 years), 23.9, 28.2,
36.2, and 11.6 % were administered atorvastatin 10, 20, 40,
and 80 mg, respectively [14]. Across all doses, the mean
LDL-C level was 81 ± 27 mg/dL, and 46.5 % had LDL-C
\77 mg/dL [14]. In an analysis of chart reviews of two
health insurance databases, 21.8, 29.6, 29.9, and 18.7 %
(GE Centricity EMR) and 25.4, 32.9, 27.8, and 14.0 %
(Humana Medicare) received 10, 20, 40, and 80 mg/day
doses of atorvastatin, respectively [24]. The mean follow-
up LDL-C levels were 83 ± 30 and 88 ± 31 mg/dL for the
GE Centricity EMR and Humana Medicare cohorts,
respectively. Regardless of dose, only 28.3–34.8 % of
patients had LDL-C\70 mg/dL [24].
Our data show a mean LDL-C level of 116.3 mg/dL.
Importantly, only 10.5 % of patients reached LDL-C val-
ues below 70 mg/dL. These findings confirm earlier reports
from clinical practice suggesting that physicians are
reluctant to administer high atorvastatin doses. Registries
such as DYSIS [2] and 2L [11] report simvastatin doses in
the lower or intermediate range. DISCOVER did not
investigate reasons for the preference for low atorvastatin
doses. It is possible that physicians want to avoid side
effects associated with higher doses. Indeed, muscle-re-
lated adverse events, cognitive and memory problems, and
increase of liver enzymes have been reported to occur more
frequently at higher doses [8, 30]. Generally a 5–10 % rate
of treatment-associated adverse events is associated with
statin use in randomised clinical trials. [16] Under clinical
practice conditions, the observed rates appear to be higher,
probably owing to the higher proportion of patients with
various comorbidities, with complex concomitant medica-
tion patterns or further factors that might complicate
pharmacotherapy (such as alcohol consumption) [23]. For
example, in a study in Boston, 17.4 % of patients reported
side effects, and 53.1 % had at least one therapy inter-
ruption [38]. Other possible explanations include a lack of
awareness/communication of the clinical trial data and the
respective guidelines.
Our analysis showed that patients with concomitant
CHD and DM were better managed in terms of LDL-C
goal attainment, and treated with higher atorvastatin doses
compared to patients who had only one of these condi-
tions. This finding is in line with earlier studies in Ger-
many and other countries that showed that patients with
cardiovascular conditions are treated more intensively at a
later stage of the disease, after complications have
occurred [1, 32].
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Limitations
The current study collected data retrospectively at one time
point. However, the majority of patients were under
maintenance therapy which allows a reliable snapshot of
the current situation. In prospective observational studies,
the rate of patients with achieved target values usually
increases between the inclusion and the follow-up visits.
This might be due to the study situation, but also due to the
feedback of target values for the individual patient. DIS-
COVER used various quality measures and plausibility
checks, included patients in all regions of Germany, and
stipulated the consecutive inclusion of eligible patients at
the sites. Site selection focused on those physicians who
usually make treatment decisions on statin use. General
practitioners/family physicians, internists and cardiologists
accounted for 64.7, 26.2 and 6.7 % in our study. The shares
of these physician groups among all active German
physicians are 42.0, 10.2, and 1.2 %, respectively [3]. As
only few inclusion/exclusion criteria applied, typical
patients under real life conditions were documented
including those with comorbidities and concomitant med-
ication. Notably, in non-participating centers and non-
participating patients the situation may be different, as
those willing to participate may be more adherent to
guideline-oriented therapy compared to those declining. No
data on medication adherence to statins were collected [7];
however, use of generic drugs compared to the originals
likely plays no major role for adherence [28]. Lastly, the
LDL-C levels of patients before the initiation of drug
treatment were not known, but would have been of interest
to assess the percentage lipid-lowering effect of atorvas-
tatin compared to the situation in the untreated patient.
In conclusion, LDL-C target achievement rates as stipu-
lated by current EAS/ESC guidelines for high-risk individ-
uals under conditions of current clinical practice often were
not met despite treatment with the potent lipid-lowering drug
atorvastatin. Atorvastatin was prescribed at relatively low
doses (mean 28 mg/day). Only one in ten patients on ator-
vastatin reached the LDL-C target of\70 mg/dL, which is
substantially less than rates achieved in other countries.
Physicians very often stated that their patients had achieved
their individual lipid targets which were in stark contrast to
the low achievement rates as evidenced by objective mea-
surements of LDL-C values. Better communication of clin-
ical evidence and the guidelines appears to be needed.
Improved lipid management of these high cardiovascular
risk patients can be achieved by using higher doses of potent
statins and/or combination therapy.
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